Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on May 3, 2024, covering events occurring on April 30, 2024. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is a significant leadership transition effective April 30, 2024:
- Anthony Amato was appointed as Director, President, Chief Executive Officer (CEO), and Principal Executive Officer.
- Mr. Hrkac resigned as President and Principal Executive Officer but will continue to serve as a Director and Acting Chief Financial Officer (CFO).
- Mr. Amato previously served on the Company's advisory board (Jan 2021–Feb 2024) and as a consultant (since March 2024).
Guidance, Outlook, and Management Commentary
Management commentary highlights Mr. Amato's background as a business leader with experience in business development, team building, and optimizing profits. He founded InQuest Science in 2017 and acquired Bridge Associates International Pharmaceutical Consulting in 2020. The Board views his appointment as a strategic move to guide the team toward aggressive targets. No specific financial guidance, risk factors, or contingencies were disclosed in this filing.
Investor Verification Checklist
- Verify the exact scope of Mr. Hrkac's remaining duties as Acting CFO.
- Review the press release (Exhibit 99.1) for additional strategic details regarding the new CEO's vision.
- Confirm if any compensatory arrangements or employment agreements were executed for Mr. Amato (noted as none requiring disclosure under Item 404(a) in this text).
- Check subsequent filings for the first financial results under the new leadership.